2004
DOI: 10.2337/diabetes.53.5.1187
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for treating type 2 diabetes. We explored the effect of short-term (1 week) treatment with a GLP-1 derivative, liraglutide (NN2211), on 24-h dynamics in glycemia and circulating free fatty acids, islet cell hormone profiles, and gastric emptying during meals using acetaminophen. Furthermore, fasting endogenous glucose release and gluconeogenesis (3-3 Hglucose infusion and 2 H 2 O ingestion, respectively) were determined, and aspects of panc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

16
336
3
2

Year Published

2004
2004
2024
2024

Publication Types

Select...
5
5

Relationship

1
9

Authors

Journals

citations
Cited by 400 publications
(357 citation statements)
references
References 56 publications
16
336
3
2
Order By: Relevance
“…Liraglutide did not affect fasting glucagon, but decreased the 24-h glucagon AUC, which included three standardised meals, and the decrease following a protein-rich dinner was particularly large. Treatment with liraglutide reduced glucagon levels relative to placebo (by ∼17%) during a hyperglycaemic (15 mmol/l) clamp, and the glucagon AUC during an arginine stimulation test performed during the hyperglycaemic clamp was also reduced (by ∼16%) [103]. This outcome contrasts with some earlier negative results with acute administration of liraglutide (see above) and suggests that this GLP-1 derivative can affect alpha cell function during chronic treatment.…”
Section: Acute Effects Of Exogenous and Endogenous Glp-1 On Alpha Celmentioning
confidence: 65%
“…Liraglutide did not affect fasting glucagon, but decreased the 24-h glucagon AUC, which included three standardised meals, and the decrease following a protein-rich dinner was particularly large. Treatment with liraglutide reduced glucagon levels relative to placebo (by ∼17%) during a hyperglycaemic (15 mmol/l) clamp, and the glucagon AUC during an arginine stimulation test performed during the hyperglycaemic clamp was also reduced (by ∼16%) [103]. This outcome contrasts with some earlier negative results with acute administration of liraglutide (see above) and suggests that this GLP-1 derivative can affect alpha cell function during chronic treatment.…”
Section: Acute Effects Of Exogenous and Endogenous Glp-1 On Alpha Celmentioning
confidence: 65%
“…Nonetheless, evidence from the literature suggests that the increased GLP-1 levels reported with colesevelam treatment could mediate these effects. In type 2 diabetes, liraglutide, a long-acting GLP-1 derivative, decreased fasting EGP as a result of reduced glycogenolysis [40], and increasing GLP-1 concentrations by dipeptidyl peptidase-4 inhibition with vildagliptin increased hepatic glucose disposal [41]. In healthy people, the infusion of GLP-1 decreased fasting EGP and tended to increase plasma glucose clearance independent of changes in insulin and glucagon concentrations [42].…”
Section: Discussionmentioning
confidence: 99%
“…This confers affinity for and binding to albumin and, as a result, protects the molecule both from DPP-IV and renal elimination. The plasma half life of this compound is 12 h, and it therefore provides exposure for more than 24 h after a single injection [71]. The compound seems to possess all of the activities of native GLP-1 [72].…”
Section: Stable Analogues and Glp-1 Receptor Activatorsmentioning
confidence: 99%